International Clinical Trial: Adbelimab combined with nimotuzumab (chemotherapy-free) as neoadjuvant therapy for resectable locally advanced squamous cell carcinoma of the head and neck: A single-center, single-arm, open-label, Phase II clinical trial

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122175) titled 'Adbelimab combined with nimotuzumab (chemotherapy-free) as neoadjuvant therapy for resectable locally advanced squamous cell carcinoma of the head and neck: A single-center, single-arm, open-label, Phase II clinical trial' on April 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital,Sun Yat-sen University

Condition: Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-04-09

Target Sample Size: test group:39;

Countries of Recruitment: China

To know more, vi...